Vaccine immunogenicity and efficacy vary considerably by diluent used for aluminum hydroxide adjuvant

Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California; the David Geffen School of Medicine at UCLA, Los Angeles, California

^* To whom correspondence should be addressed. Email: bspellberg{at}labiomed.org.

	Abstract

We are developing an anti-candidal vaccine using the Als3p recombinant N-terminus (rAls3p-N). We report that although more rAls3p-N was bound by aluminum hydroxide diluted in saline than PBS, its immunogenicity and efficacy was superior in PBS. Thus protein binding, by itself, may not predict the efficacy of some aluminum-adjuvanted vaccines.